Profusa (NASDAQ:PFSA) Shares Set to Reverse Split on Monday, February 9th

Profusa, Inc. (NASDAQ:PFSA)’s stock is going to reverse split on the morning of Monday, February 9th. The 1-75 reverse split was announced on Thursday, February 5th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, February 6th.

Profusa Stock Performance

PFSA traded down $0.03 during trading hours on Thursday, hitting $0.05. The stock had a trading volume of 14,921,879 shares, compared to its average volume of 16,309,144. Profusa has a 1 year low of $0.05 and a 1 year high of $2.40. The firm’s fifty day simple moving average is $0.11. The stock has a market capitalization of $4.74 million, a PE ratio of -0.02 and a beta of -0.14.

Profusa (NASDAQ:PFSA) last released its quarterly earnings data on Wednesday, November 19th. The company reported ($0.70) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Profusa in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.